Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy?

被引:33
|
作者
Cosar, Rusen [1 ]
Uzal, Cem [1 ]
Tokatli, Fusun [2 ]
Denizli, Bengu [1 ]
Saynak, Mert [1 ]
Turan, Nesrin [3 ]
Uzunoglu, Sernaz [4 ]
Ozen, Alaattin [1 ]
Sezer, Atakan [5 ]
Ibis, Kamuran [1 ]
Uregen, Burcu [1 ]
Yurut-Caloglu, Vuslat [1 ]
Kocak, Zafer [1 ]
机构
[1] Trakya Univ Hosp, Dept Radiat Oncol, Edirne, Turkey
[2] Medicana Hosp, Dept Radiat Oncol, Istanbul, Turkey
[3] Trakya Univ Hosp, Dept Biostat, Edirne, Turkey
[4] Trakya Univ Hosp, Dept Internal Med, Div Med Oncol, Edirne, Turkey
[5] Trakya Univ Hosp, Dept Surg, Edirne, Turkey
关键词
HIGH-RISK; LOCOREGIONAL RECURRENCE; PROGNOSTIC-FACTOR; RADIOTHERAPY; SURVIVAL; RATIO; MASTECTOMY; STATEMENT; NUMBER;
D O I
10.1186/1748-717X-6-28
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: We aimed to evaluate retrospectively the correlation of loco-regional relapse (LRR) rate, distant metastasis (DM) rate, disease free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) patients who are at intermediate risk for LRR (T1-2 tumor and 1-3 positive axillary nodes) treated with or without postmastectomy radiotherapy (PMRT) following modified radical mastectomy (MRM). Methods: Ninety patients, with T1-T2 tumor, and 1-3 positive nodes who had undergone MRM received adjuvant systemic therapy with (n = 66) or without (n = 24) PMRT. Patient-related characteristics (age, menopausal status, pathological stage/tumor size, tumor location, histology, estrogen/progesterone receptor status, histological grade, nuclear grade, extracapsular extension, lymphatic, vascular and perineural invasion and ratio of involved nodes/dissected nodes) and treatment-related factors (PMRT, chemotherapy and hormonal therapy) were evaluated in terms of LRR and DM rate. The 5-year Kaplan-Meier DFS and OS rates were analysed. Results: Differences between RT and no-RT groups were statistically significant for all comparisons in favor of RT group except OS: LRR rate (3% vs 17%, p = 0.038), DM rate (12% vs 42%, p = 0.004), 5 year DFS (82.4% vs 52.4%, p = 0.034), 5 year OS (90,2% vs 61,9%, p = 0.087). In multivariate analysis DM and lymphatic invasion were independent poor prognostic factors for OS. Conclusion: PMRT for T1-2, N1-3 positive BC patients has to be reconsidered according to the prognostic factors and the decision has to be made individually with the consideration of long-term morbidity and with the patient approval.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Postmastectomy irradiation in breast in breast cancer patients with T1-2 and 1-3 positive axillary lymph nodes: Is there a role for radiation therapy?
    Rusen Cosar
    Cem Uzal
    Fusun Tokatli
    Bengu Denizli
    Mert Saynak
    Nesrin Turan
    Sernaz Uzunoglu
    Alaattin Ozen
    Atakan Sezer
    Kamuran Ibis
    Burcu Uregen
    Vuslat Yurut-Caloglu
    Zafer Kocak
    [J]. Radiation Oncology, 6
  • [2] Impact of postmastectomy radiation therapy in T1-2 breast cancer patients with 1-3 positive axillary lymph nodes
    Yin, Hang
    Qu, Yuanyuan
    Wang, Xiaoyuan
    Ma, Tengchuang
    Zhang, Haiyang
    Zhang, Yu
    Li, Yang
    Zhang, Siliang
    Ma, Hongyu
    Xing, Enkang
    Liu, Xueying
    Xu, Qingyong
    [J]. ONCOTARGET, 2017, 8 (30) : 49564 - 49573
  • [3] Role of postmastectomy radiation therapy in breast cancer patients with T1-2 and 1-3 positive lymph nodes
    Cihan, Yasemin Benderli
    Sarigoz, Talha
    [J]. ONCOTARGETS AND THERAPY, 2016, 9 : 5587 - 5595
  • [4] Therapeutic value of postmastectomy radiation therapy for T1-2 breast cancer with 1-3 positive lymph nodes
    Kimura, Yuri
    Sasada, Shinsuke
    Goda, Noriko
    Kajitani, Keiko
    Emi, Akiko
    Masumoto, Norio
    Kadoya, Takayuki
    Okada, Morihito
    [J]. JOURNAL OF RADIATION ONCOLOGY, 2019, 8 (03) : 323 - 328
  • [5] Analysis of Breast Cancer Patients with T1-2 Tumors and 1-3 Positive Lymph Nodes Treated with or without Postmastectomy Radiation Therapy
    Gilmore, Richard C.
    Sebai, Mohamad E.
    Psoter, Kevin J.
    Prasath, Vishnu
    Siotos, Charalampos
    Broderick, Kristen P.
    Jacobs, Lisa K.
    Harvey, Susan C.
    Habibi, Mehran
    [J]. SCIENTIFIC REPORTS, 2020, 10 (01)
  • [6] Analysis of Breast Cancer Patients with T1-2 Tumors and 1-3 Positive Lymph Nodes Treated with or without Postmastectomy Radiation Therapy
    Gilmore, Richard C.
    Sebai, Mohamad E.
    Psoter, Kevin J.
    Siotos, Charalampos
    Grauer, Mary Janet
    Irwin, Stephanie
    Broderick, Kristen P.
    Jacobs, Lisa K.
    Habibi, Mehran
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2017, 225 (04) : E60 - E60
  • [7] Analysis of Breast Cancer Patients with T1-2 Tumors and 1-3 Positive Lymph Nodes Treated with or without Postmastectomy Radiation Therapy
    Richard C. Gilmore
    Mohamad E. Sebai
    Kevin J. Psoter
    Vishnu Prasath
    Charalampos Siotos
    Kristen P. Broderick
    Lisa K. Jacobs
    Susan C. Harvey
    Mehran Habibi
    [J]. Scientific Reports, 10
  • [8] Postmastectomy Radiation Therapy (PMRT) and Overall Survival (OS) of Breast Cancer Patients with T1-2 and 1-3 Positive Axillary Lymph Nodes: A SEER Data Analysis
    Kubicky, C. Dai
    Marquez, C. M.
    Wang, S. J.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S205 - S205
  • [9] Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients
    Zhao, Jia-ming
    An, Qi
    Sun, Chao-nan
    Li, Yu-bing
    Qin, Zi-lan
    Guo, Hong
    Zeng, Xue
    Zhang, Yao-tian
    Wei, Lin-lin
    Han, Ning
    Sun, Shi-chen
    Zhang, Na
    [J]. BREAST CANCER, 2021, 28 (02) : 298 - 306
  • [10] Improved Survival with Postmastectomy Radiation Therapy in Premenopausal Patients With T1-T2 Breast Cancer and 1-3 Positive Lymph Nodes
    Mu, Yijia
    Diego, Emilia
    McAuliffe, Priscilla
    McGuire, Kandace
    Soran, Atilla
    Bonaventura, Marguerite
    Johnson, Ronald
    Beriwal, Sushil
    Ahrendt, Gretchen
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2016, 23 : 112 - 113